c1qtnf12 Antibody

What is C1QTNF12 and what are its known biological functions?

C1QTNF12 (Complement C1q tumor necrosis factor-related protein 12) is a novel adipokine that functions as an anti-diabetic factor in the metabolic regulatory network. It serves as a critical component linking adipose tissue to systemic glucose metabolism. C1QTNF12 is predicted to enable hormone activity and is involved in multiple important biological processes, including negative regulation of gluconeogenesis, positive regulation of glucose import, enhancement of insulin receptor signaling pathways, negative regulation of inflammatory responses, positive regulation of cell communication, and regulation of glucose metabolic processes . The protein is primarily located in the extracellular region and is active in extracellular space, consistent with its function as a secreted adipokine . Research has demonstrated that C1QTNF12 plays a significant role in metabolic homeostasis, making it an important target for metabolic disease research.

How is C1QTNF12 expression distributed across different tissues?

C1QTNF12 exhibits a distinct tissue expression pattern that can be analyzed using tissue cDNA panels. Expression analyses have been conducted on mouse and human tissue panels where samples were pooled from multiple individuals (200-1000 mice and 3-15 humans per tissue type). These analyses reveal that C1QTNF12 is predominantly expressed in adipose tissue, although it can also be detected at lower levels in other metabolic tissues . Researchers interested in tissue-specific expression should consider using quantitative RT-PCR analysis, which has been successfully employed to measure CTRP12 expression in various tissues and cell lines. For optimal results, RNA isolation should be performed using TRIzol® followed by reverse transcription with Superscript II RNase H-reverse transcriptase, and qPCR analysis can be conducted using standard protocols with SyBR® Green PCR Master Mix on systems such as the Applied Biosystems Prism 7500 sequence detection system .

What criteria should be considered when selecting a C1QTNF12 antibody for research?

When selecting a C1QTNF12 antibody for research, several critical factors should be evaluated:

• Specificity and cross-reactivity: Verify the antibody's specificity for C1QTNF12 and assess potential cross-reactivity with other C1Q family proteins. For instance, commercial antibodies like the rabbit polyclonal against human C1QTNF12 are developed using specific immunogens such as E. coli-derived recombinant Human C1QTNF12 (Gly92-Gln241) .

• Species reactivity: Confirm the antibody's reactivity with your species of interest. Commercial options are available for multiple species including human, mouse, rat, and non-human primates .

• Application compatibility: Ensure the antibody is validated for your intended application. For example, the polyclonal antibody from Abinscience (HV830014) is validated for ELISA, IHC, and WB applications , while Sigma-Aldrich's anti-C1QTNF12 antibody is recommended for immunofluorescence (0.25-2 μg/mL) and immunohistochemistry (1:50-1:200) .

• Clonality: Consider whether a monoclonal or polyclonal antibody better suits your research needs. For C1QTNF12, polyclonal antibodies like those from Sigma-Aldrich and Abinscience are well-characterized options .

• Validation data: Review the available validation data, including images from immunohistochemistry, Western blots, or immunofluorescence experiments to assess antibody performance.

How can I validate the specificity of a C1QTNF12 antibody?

Validating antibody specificity is essential for reliable research outcomes. For C1QTNF12 antibodies, consider the following validation approaches:

• Positive and negative controls: Use tissues or cell lines with known C1QTNF12 expression levels. Adipose tissue serves as an excellent positive control, while tissues with minimal expression can serve as negative controls .

• Immunogen blocking: Pre-incubate the antibody with the immunizing peptide (e.g., recombinant C1QTNF12) before application to verify that signal loss occurs when the antibody's binding sites are occupied.

• Knockout/knockdown validation: Test the antibody in C1QTNF12 knockout models or in cells where C1QTNF12 has been knocked down using siRNA to confirm signal reduction.

• Multiple antibody verification: Compare results using antibodies targeting different epitopes of C1QTNF12 to ensure consistent detection patterns.

• Western blot analysis: Verify that the antibody detects a band of the expected molecular weight (approximately 37 kDa for full-length human C1QTNF12) .

• Recombinant protein controls: Use purified recombinant C1QTNF12 protein, such as those available from GeneMedi for various species, as positive controls for antibody validation .

What are the optimal protocols for using C1QTNF12 antibodies in immunohistochemistry?

For optimal immunohistochemistry (IHC) results with C1QTNF12 antibodies, consider this methodology:

• Sample preparation: Fix tissues in 10% neutral buffered formalin and embed in paraffin. Cut sections at 4-6 μm thickness.

• Antigen retrieval: Perform heat-induced epitope retrieval in citrate buffer (pH 6.0) for 20 minutes. This step is crucial as it helps unmask antigens that may have been cross-linked during fixation.

• Blocking: Block endogenous peroxidase activity with 3% hydrogen peroxide, followed by protein blocking with 5% normal serum.

• Primary antibody incubation: Apply the C1QTNF12 antibody at the recommended dilution. For instance, Sigma-Aldrich's anti-C1QTNF12 should be used at a dilution of 1:50-1:200 . Incubate overnight at 4°C in a humidified chamber.

• Detection system: Use an appropriate secondary antibody and detection system compatible with your primary antibody. For rabbit-derived antibodies like most C1QTNF12 antibodies, an anti-rabbit HRP-conjugated secondary antibody is suitable.

• Visualization: Develop with DAB (3,3'-diaminobenzidine) substrate and counterstain with hematoxylin.

• Controls: Include positive control tissues (adipose tissue) and negative controls (primary antibody omission) in each run.

How can C1QTNF12 antibodies be effectively used in Western blot applications?

For effective Western blot detection of C1QTNF12, follow these methodological guidelines:

• Sample preparation: Extract proteins from tissues or cells using RIPA buffer supplemented with protease inhibitors. For adipose tissue samples, additional steps may be needed to remove lipids.

• Protein quantification: Determine protein concentration using BCA or Bradford assay to ensure equal loading.

• SDS-PAGE separation: Load 20-50 μg of protein per lane on 10-12% SDS-PAGE gels. C1QTNF12 has a molecular weight of approximately 37 kDa.

• Transfer: Transfer proteins to PVDF or nitrocellulose membranes using standard wet or semi-dry transfer systems.

• Blocking: Block membranes with 5% non-fat milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute the C1QTNF12 antibody according to manufacturer recommendations (typically 1:500-1:2000) and incubate overnight at 4°C.

• Secondary antibody: Apply HRP-conjugated anti-rabbit secondary antibody (for rabbit-derived primary antibodies) at 1:5000-1:10000 dilution for 1 hour at room temperature.

• Detection: Visualize using enhanced chemiluminescence (ECL) substrate and document using a digital imaging system.

• Controls: Include recombinant C1QTNF12 protein as a positive control and verify equal loading using housekeeping proteins like β-actin or GAPDH.

What protocols are recommended for immunofluorescence detection of C1QTNF12?

For immunofluorescence detection of C1QTNF12, implement this methodology:

• Cell/tissue preparation: For cultured cells, grow on coverslips and fix with 4% paraformaldehyde for 15 minutes. For tissue sections, prepare frozen or paraffin sections as appropriate.

• Permeabilization: Permeabilize with 0.1-0.3% Triton X-100 in PBS for 10 minutes (for intracellular epitopes).

• Blocking: Block with 5-10% normal serum (from the species in which the secondary antibody was raised) for 1 hour at room temperature.

• Primary antibody: Apply C1QTNF12 antibody at the recommended concentration (e.g., 0.25-2 μg/mL for Sigma-Aldrich's antibody) . Incubate overnight at 4°C.

• Secondary antibody: Use fluorophore-conjugated secondary antibodies (e.g., Alexa Fluor) at 1:200-1:1000 dilution. Incubate for 1 hour at room temperature protected from light.

• Nuclear counterstaining: Counterstain nuclei with DAPI (1 μg/mL) for 5 minutes.

• Mounting: Mount slides with anti-fade mounting medium.

• Imaging: Capture images using confocal or fluorescence microscopy, optimizing exposure settings to avoid photobleaching.

What are common issues encountered when using C1QTNF12 antibodies and how can they be resolved?

When working with C1QTNF12 antibodies, researchers may encounter several challenges:

• High background signal:

  • Cause: Insufficient blocking, excessive antibody concentration, or non-specific binding.

  • Solution: Optimize blocking conditions (try different blocking agents like BSA, normal serum, or commercial blockers), reduce primary antibody concentration, increase washing duration/frequency, or try a different detection system.

• Weak or no signal:

  • Cause: Inadequate antigen retrieval, low target expression, antibody degradation, or improper storage.

  • Solution: Optimize antigen retrieval methods, ensure proper antibody storage (most C1QTNF12 antibodies should be stored at -20°C to -80°C for long-term storage) , verify target expression in your sample using positive controls, or try a more sensitive detection system.

• Multiple bands in Western blot:

  • Cause: Protein degradation, non-specific binding, or detection of post-translational modifications.

  • Solution: Use fresh samples with protease inhibitors, optimize antibody dilution, increase blocking stringency, or verify which bands correspond to specific forms of C1QTNF12 (e.g., full-length vs. cleaved forms) .

• Inconsistent results:

  • Cause: Variability in sample preparation, antibody quality between lots, or protocol inconsistencies.

  • Solution: Standardize sample collection and processing, validate each new antibody lot, and follow a detailed, consistent protocol.

How should results from C1QTNF12 antibody-based experiments be interpreted in metabolic disease research?

When interpreting C1QTNF12 antibody results in metabolic disease research:

• Expression level changes: C1QTNF12 expression alterations may correlate with metabolic states. Decreased levels have been associated with insulin resistance and obesity, while increased levels may indicate improved metabolic health .

• Localization patterns: Consider both tissue distribution and subcellular localization. As a secreted protein, C1QTNF12 should be detected in the extracellular space and potentially intracellularly during synthesis and processing .

• Correlation with metabolic parameters: Analyze C1QTNF12 expression in relation to glucose tolerance, insulin sensitivity, and inflammatory markers. C1QTNF12 has been shown to improve insulin sensitivity and glucose homeostasis in experimental models .

• Form-specific detection: Distinguish between different forms of C1QTNF12 (full-length vs. cleaved forms) as they may have distinct biological activities .

• Integration with functional data: Combine antibody-based detection with functional assays such as glucose tolerance tests (GTT) and insulin tolerance tests (ITT) to establish correlations between C1QTNF12 levels and physiological outcomes .

How can C1QTNF12 antibodies be utilized in studying the relationship between adipose tissue dysfunction and insulin resistance?

C1QTNF12 antibodies offer valuable tools for investigating the complex relationship between adipose tissue dysfunction and insulin resistance:

• Tissue expression profiling: Use immunohistochemistry with C1QTNF12 antibodies to map expression patterns across different adipose depots (subcutaneous vs. visceral) in normal and insulin-resistant states.

• Cell-specific expression: Employ immunofluorescence co-staining with markers for adipocytes, macrophages, and other cell types to determine which cells produce C1QTNF12 in adipose tissue.

• Intervention studies: Monitor changes in C1QTNF12 expression using Western blot or ELISA following interventions that improve insulin sensitivity (exercise, weight loss, pharmaceutical agents) to establish temporal relationships.

• Secretion analysis: Quantify secreted C1QTNF12 in adipose tissue explant culture media using antibody-based assays to assess its production under different metabolic conditions.

• Pathway analysis: Combine C1QTNF12 detection with phospho-specific antibodies against components of the insulin signaling pathway (e.g., IRS-1, Akt) to elucidate mechanistic connections between C1QTNF12 and insulin action.

• In vivo functional studies: Correlate C1QTNF12 expression with metabolic parameters in animal models using techniques such as glucose tolerance tests (GTT) and insulin tolerance tests (ITT) .

What are the latest methodological approaches for investigating C1QTNF12 signaling mechanisms using specific antibodies?

Advanced methodological approaches for investigating C1QTNF12 signaling include:

• Proximity ligation assay (PLA): This technique can detect protein-protein interactions between C1QTNF12 and potential receptors or downstream signaling molecules with high sensitivity and specificity, requiring specific antibodies against both interaction partners.

• Phospho-proteomics combined with immunoprecipitation: Use C1QTNF12 antibodies for immunoprecipitation followed by mass spectrometry to identify phosphorylation changes in signaling proteins after C1QTNF12 stimulation.

• ChIP-seq analysis: Investigate transcriptional changes induced by C1QTNF12 signaling by performing chromatin immunoprecipitation with antibodies against transcription factors activated downstream of C1QTNF12.

• Single-cell analysis: Combine C1QTNF12 antibody-based detection with single-cell RNA-seq to identify cell populations responsive to C1QTNF12 and characterize their transcriptional profiles.

• Live-cell imaging: Use fluorescently labeled C1QTNF12 antibodies or antibodies against tagged C1QTNF12 for real-time tracking of protein trafficking and internalization.

• Antibody-mediated neutralization: Utilize neutralizing antibodies against C1QTNF12 to block its function in experimental systems, providing insights into its physiological roles.

How can researchers design experiments to investigate the therapeutic potential of targeting the C1QTNF12 pathway?

To investigate the therapeutic potential of targeting C1QTNF12, researchers can design experiments incorporating these approaches:

• Gain-of-function studies: Use adenoviral vectors expressing C1QTNF12 to increase its levels in vivo, followed by metabolic phenotyping including glucose tolerance tests (GTT) and insulin tolerance tests (ITT) .

• Loss-of-function studies: Employ neutralizing antibodies against C1QTNF12 or genetic approaches (CRISPR/Cas9, siRNA) to reduce C1QTNF12 activity, then assess metabolic consequences.

• Recombinant protein therapy: Administer purified recombinant C1QTNF12 protein to animal models of metabolic disease and evaluate improvements in glucose homeostasis and insulin sensitivity.

• Pathway modulation: Identify compounds that enhance C1QTNF12 expression or signaling using cell-based screening assays with antibody-based detection methods.

• Biomarker development: Establish ELISA or other quantitative assays using C1QTNF12 antibodies to evaluate circulating levels in clinical samples, correlating with disease states and treatment responses.

• Combination therapy approaches: Investigate synergistic effects between C1QTNF12-targeted interventions and established anti-diabetic treatments using animal models and appropriate antibody-based detection methods.

• Long-term efficacy and safety studies: Design longitudinal studies to assess the sustained benefits and potential side effects of C1QTNF12 pathway modulation, using antibodies to monitor target engagement and pathway activation.

What role might C1QTNF12 play in inflammatory regulation, and how can researchers investigate this using antibody-based techniques?

C1QTNF12 has been implicated in negative regulation of inflammatory responses , suggesting an important immunomodulatory function. To investigate this aspect:

• Inflammation models: Use C1QTNF12 antibodies to monitor expression changes during acute and chronic inflammation in various tissues.

• Macrophage polarization: Employ immunofluorescence co-staining with C1QTNF12 antibodies and markers for M1/M2 macrophages to determine relationships between C1QTNF12 and macrophage phenotypes in adipose tissue.

• Cytokine profiling: Correlate C1QTNF12 levels (detected by antibody-based methods) with pro- and anti-inflammatory cytokine expression in metabolic tissues.

• Intervention studies: Administer recombinant C1QTNF12 to inflammatory models and assess effects on inflammatory gene expression and signaling pathways using antibody-based techniques such as Western blotting and immunohistochemistry.

• Cell culture systems: Use antibodies to detect C1QTNF12 production by adipocytes under different inflammatory stimuli (e.g., TNF-α, IL-6), and examine how recombinant C1QTNF12 treatment affects inflammatory responses in immune and metabolic cells.

How can researchers optimize multi-omics approaches that incorporate C1QTNF12 antibody-based data?

Integration of C1QTNF12 antibody-based data into multi-omics research approaches requires careful methodological considerations:

• Integrated sample collection: Design studies to obtain matched samples for antibody-based protein detection, transcriptomics, metabolomics, and other omics approaches from the same experimental subjects.

• Quantitative proteomics: Combine immunoprecipitation using C1QTNF12 antibodies with mass spectrometry to identify interaction partners and post-translational modifications.

• Spatial transcriptomics with protein detection: Integrate in situ hybridization for C1QTNF12 mRNA with immunofluorescence using C1QTNF12 antibodies to correlate transcript and protein expression at the cellular level.

• Single-cell multi-omics: Combine single-cell RNA-seq with protein detection using antibody-based methods like CITE-seq to correlate C1QTNF12 expression with cellular transcriptional states.

• Data integration frameworks: Develop computational approaches to integrate antibody-based protein quantification data with other omics datasets to build comprehensive models of C1QTNF12 function in metabolic regulation.

• Validation across platforms: Use C1QTNF12 antibodies to validate findings from transcriptomic or proteomic studies in independent samples and experimental systems.